Toulouse Cedex 9

• A study to understand if sotagliflozin improves symptoms and is safe in people with hypertrophic cardiomyopathy Recruiting
  2024-513869-39-00 5 2025-06-27 Obstructive Cardiomyopathy, Hypertrophic
• A Phase III study to evaluate the efficacy of INM004 (Shiga antitoxin) in pediatric patients with Shiga toxin-producing Escherichia coli-ass … Recruiting
  2024-512412-22-00 5 2025-06-24 Hemolytic Uremic Syndrome
• A study to investigate efficacy and safety of SAR441566 in patients with ulcerative colitis Recruiting
  2025-520705-12-00 4 2025-06-24 Colitis Ulcerative
• Immediate versus delayed treatment with azathioprine or rituximab in anti-myelin oligodendrocytes glycoprotein (anti-MOG) antibodies associa … Recruiting
  2024-516243-81-00 5 2025-06-23 myelin oligodendrocytes glycoprotein antibody associated diseases (MOG
• Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction Recruiting
  2024-519219-32-00 5 2025-06-23 Heart Failure With Reduced Ejection Fraction
• IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as p … Recruiting
  2024-517325-43-00 4 2025-06-19 multiple myeloma
• A multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of BP1.4979 in adult p … Recruiting
  2024-517996-19-00 4 2025-06-19 Primary premature ejaculation
• A Phase 2 Study evaluating Epcoritamab in subjects with relapsed and refractory primary diffuse large B-cell lymphoma of the CNS treated wit … Recruiting
  2023-505834-84-00 10 2025-06-17 relapsed and refractory primary diffuse large B-cell lymphoma of the C
• A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration ( … Recruiting
  2023-510294-34-00 5 2025-06-12 small lymphocytic lymphoma (SLL)
• A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients with C3-Glomerulopathy Recruiting
  2024-517992-19-00 1 2025-06-11 C3 glomerulopathy (C3G)
• Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting
  2024-513122-27-00 5 2025-06-10 Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or
• REscue of Nephrons with ALe.F02 (RENAL F02) Recruiting
  2022-502184-38-00 4 2025-06-06 Rapidly progressive glomerulonephritis
• A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's … Recruiting
  2023-509391-42-00 11 2025-06-02 Chron's Disease
• An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination with Different Treatment Regimens … Recruiting
  2024-517432-21-00 4 2025-05-30 Gynecological Cancers
• An open-label extension study to assess the efficacy and safety of ianalumab with or without study treatment withdrawal in adult participan … Recruiting
  2024-515280-60-00 5 2025-05-29 Lupus nephritis
• ATLANTIS Protamine - Antagonization of heparin with protamine sulfate to reduce all neurologic ischemic and hemorrhagic events after transca … Recruiting
  2023-504511-32-00 5 2025-05-24 Any patients ≥18 years old, eligible for transfemoral TAVI with covera
• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 5 2025-05-23 Metastatic hormone naïve prostate cancer (mHNPC)
• A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C … Recruiting
  2024-517422-25-00 5 2025-05-22 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) Recruiting
  2024-514937-39-00 5 2025-05-20 Dravet Syndrome
• A Phase 3, multicenter, open label, randomized, non-comparative two-arm study of ivosidenib monotherapy (IVO) and azacitidine monotherapy (A … Recruiting
  2023-510155-37-00 5 2025-05-08 Hypomethylating agent (HMA) naive myelodysplastic syndromes Myelodyspl
• A study of elritercept to treat transfusion-dependent anemia due to very low, low, or intermediate risk myelodysplastic syndromes Recruiting
  2024-516009-22-00 5 2025-04-30 myelodysplastic neoplasms/syndromes (MDS)
• A study to assess the effectiveness and safety of pacritinib in patients with VEXAS syndrome (PAXIS) Recruiting
  2024-516347-41-00 4 2025-04-29 VEXAS Syndrome
• A Worldwide Study Testing the New Drug Olverembatinib for Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2) Recruiting
  2024-511495-32-00 5 2025-04-16 Chronic Phase Chronic Myeloid Leukemia
• A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti … Recruiting
  2024-513053-69-00 5 2025-04-16 Moderately to Severely Active Crohn's Disease (CD)

Showing 265–288 of 893 trials